Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up

Background: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-old girls and boys was extended to assess long-ter...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Sven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, Punnee Pitisuttithum, Angels Ulied, Meera Varman, Pierre Van Damme, Edson Duarte Moreira, Jr., Daron Ferris, Stanley Block, Oliver Bautista, Nancy Gallagher, Jennifer McCauley, Alain Luxembourg
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2020-12-01
Ráidu:	Papillomavirus Research
Fáttát:	Nine-valent human papillomavirus vaccine Effectiveness Immunogenicity Long-term follow-up
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2405852120300215
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!